Metoclopramide-induced encephalopathy in parkinson disease

Southern Medical Journal

Volumn 103, Issue 2, 2010, Pages 178-180

  Robottom, Bradley J ^a   Shulman, Lisa M ^a   Anderson, Karen E ^a   Weiner, William J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Delirium; Encephalopathy; Metoclopramide; Parkinson disease; Parkinsonism

Indexed keywords

CARBIDOPA PLUS LEVODOPA; METOCLOPRAMIDE; TRIHEXYPHENIDYL;

AGED; AGGRESSION; AGITATION; ARTICLE; BODY EQUILIBRIUM; BRAIN ATROPHY; BRAIN DISEASE; CASE REPORT; CONSTIPATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; LIMB TREMOR; MALE; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PERSONALITY DISORDER; SHORT COURSE THERAPY; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; WALKING DIFFICULTY; WHEELCHAIR; WHITE MATTER;

AGED; ANTIEMETICS; CONSTIPATION; HUMANS; MALE; METOCLOPRAMIDE; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 76949107201     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181ca9b3f     Document Type: Article

References (25)

1. Baxter Healthcare Corporation. Reglan [Package Insert.] Deerfield, IL, Baxter Healthcare Corporation, 2003.
2. Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med 1986;146:2070-2071.
3. Indo T, Ando K. Metoclopramide-induced parkinsonism. Clinical characteristics of ten cases. Arch Neurol 1982;39:494-496.
4. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J 1982;126:23-25.
5. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149:2486-2492.
6. Mazza A, Ruffatti S, Pessina AC, et al. Tetanus-like syndrome secondary to metoclopramide administration. Ann Ital Med Int 2000;15:301-302.
7. Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med 1992;1:271-278.
8. Dubow JS, Leikin J, Rezak M. Acute chorea associated with metoclopramide use. Am J Ther 2006;13:543-544.
9. Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull 2002; 36:82-93.
10. Hyser CL, Drake ME Jr. Myoclonus induced by metoclopramide therapy. Arch Intern Med 1983;143:2201-2202.
11. Weddington WW Jr, Banner A. Organic affective syndrome associated with metoclopramide: case report. J Clin Psychiatry 1986;47:208-209.
12. Fishbain DA, Rogers A. Delirium secondary to metoclopramide hydrochloride. J Clin Psychopharmacol 1987;7:281-282.
13. Cunningham D, Dicato M, Verweij J, et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone, plus lorazepam. Ann Oncol 1996;7:277-282.
14. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008;23:401-404.
15. Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med 1990;6:269-283.
16. Adams C. Metoclopramide and depression. Ann Intern Med 1985;103:960.
17. Friend K, Young R. Late-onset major depression with delusions after metoclopramide treatment. Am J Geriatr Psychiatry 1997;5:79-82.
18. Masters JC, O'Grady M. Adverse reactions to metoclopramide (reglan) presenting as depression in a bone marrow transplant patient. Medsurg Nurs 1995;4:481-485.
19. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230-1234.
20. Tornetta FJ. Clinical studies with the new antiemetic, metoclopramide. Anesth Analg 1969;48:198-204.
21. Eggers C. [Non-delirious toxic psychoses in children.] Z Kinderheilkd 1975;119:71-86 [in German].
22. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
23. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000;16:365-379.
24. Mehta MA, Sahakian BJ, McKenna PJ, et al. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 1999;146:162-174.
25. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain Behav 2006;5:311-328.